A recent paper has provided new evidence that LSD has outstanding nootropic effects, believed to originate in the drug’s neuroplasticity promotion, in both animals and humans. Yet a previous study involving Betterlife’s BETRF BETR-001 (2-bromo-LSD) similarly demonstrated that, in the treatment of rat embryonic cortical neurons, the drug increases the structural complexity of neurons (dendrite growth and complexity) and therefore generates neural plasticity activity, generally linked to antidepressant effects.
A variety of psychedelic compounds are showing positive signs regarding the treatment of various mental health conditions without hallucinogenic effects, including DMT analogs PSL001 and PSL002 and ibogaine analog MM110.
BetterLife’s study also exhibited certain measurements of structural neuroplasticity in which their proprietary BETR-001 performed better than ketamine.
CEO Ahmad Doroudian said the results “confirm that our proprietary BETR-001, an LSD analog, retains the anti-depressant and neural plasticity activity of LSD without causing hallucination.
“The fact that BETR-001 can promote structural plasticity in the prefrontal cortex neurons indicates its therapeutic effects in depression and related disorders, providing a potential patient friendly treatment addressing a very large unmet medical need affecting large number of patients globally,” he explained.
Preclinical and IND-enabling studies stage BETR-001 is a non-hallucinogenic and non-controlled LSD derivative available for self-administration. Its synthesis patent avoids regulatory hindrances and its pending patent for composition and method of use covers treatment of depression, cluster headaches, PTSD and other neuropsychiatric and neurological conditions.
The company is also developing BETR-002, a preclinical and IND-enabling studies proprietary compound based on honokiol, the active anxiolytic ingredient of magnolia bark. Its pending patent for method of use and formulations covers treatment of anxiety-related disorders, including benzodiazepine dependence.
Photo by Milad Fakurian on Unsplash
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.